The Natural History of LDL Control in Type 2 Diabetes
A prospective study of adherence to lipid guidelines
- Diana Rucker, MD, MSC1,
- Jeffrey A. Johnson, PHD123,
- T.K. Lee, MD1,
- Dean T. Eurich, MSC23,
- Richard Z. Lewanczuk, MD, PHD1,
- Scot H. Simpson, PHARMD, MSC34,
- Ellen L. Toth, MD13 and
- Sumit R. Majumdar, MD, MPH123
- 1Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- 2Department of Public Health Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- 3Institute of Health Economics, Edmonton, Alberta, Canada
- 4Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
- Address correspondence and reprint requests to Dr. Sumit R. Majumdar, University of Alberta, 2E3.07 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440-112th St., Edmonton, Alberta, Canada, T6G 2B7. E-mail: me2.majumdar{at}ualberta.ca
Article Figures & Tables
Tables
- Table 1—
Characteristics of 346 patients with type 2 diabetes according to achievement of LDL cholesterol target <2.5 mmol/l, at baseline and over 18 months of follow-up
Characteristics Baseline (cross-sectional data) Over 18 months of follow-up Originally not at target (n = 216) Originally at target (n = 130) Not at target (n = 216) Already at target (n = 130) Adjusted odds ratio (95% CI)* Never at target (n = 195) Achieved target (n = 21) Adjusted odds ratio (95% CI)* Maintains target (n = 47) Lost target (n = 83) Adjusted odds ratio (95% CI)* Age >60 years 62 50 1.8 (1.1–2.8) 62 62 — 66 41 0.6 (0.4–0.9) Female 60 52 — 62 38 — 43 59 — High school or more 28 39 — 22 40 — 23 48 2.4 (1.0–5.5) Income >$40,000/year 24 27 — 22 40 — 17 33 — Aboriginal 26 24 — 24 19 — 28 26 — Current smoker 16 21 — 30 10 — 20 22 — Median duration of diabetes (years) 5 5 — 5 7 — 5 5 — HbA1c (%) 7.1 ± 1.4 7.4 ± 1.7 — 7.1 ± 1.4 7.4 ± 1.2 — 7.3 ± 1.7 7.4 ± 1.7 — BMI >27 kg/m2 77 84 — 79 57 — 77 88 — Systolic blood pressure (mmHg) 132 ± 19 129 ± 17 — 131 ± 19 134 ± 20 — 129 ± 16 130 ± 17 — Total cholesterol (mmol/l) 5.4 ± 0.8 4.1 ± 1.0 — 5.4 ± 0.8 3.6 ± 0.3 — 3.5 ± 0.4 4.8 ± 0.5 — LDL cholesterol (mmol/l) 3.3 ± 0.6 2.0 ± 1.4 — 3.4 ± 0.5 2.3 ± 0.2 — 2.2 ± 0.3 3.0 ± 0.3 — Lipid-lowering therapy Taking 14 24 2.1 (1.2–3.6) 23 71 — 30 18 — Started NA NA NA 13 57 9.2 (3.5–24.0) 9 5 — Stopped NA NA NA 2 0 — 4 4 — -
Data are means ± SD or percent unless otherwise indicated.
- *
↵* All odds ratios adjusted for intervention status (P > 0.5, all analyses, see text) and those variables presented in the table that were significant at P < 0.05 in the relevant multivariable model. NA, not applicable; — , not included in multivariable analyses.
-
In this Issue
November 2006, 29(11)
